Target type: biologicalprocess
The chemical reactions and pathways resulting in the breakdown of glucosylceramides, any compound formed by the replacement of the glycosidic hydroxyl group of a cyclic form of glucose by a ceramide group. [GOC:ai]
Glucosylceramide catabolic process is a complex biochemical pathway that involves the breakdown of glucosylceramide (GlcCer), a sphingolipid found in the cell membrane. GlcCer is composed of a glucose molecule linked to a ceramide molecule. The breakdown of GlcCer is essential for maintaining cell membrane integrity and for proper cellular function. The process begins with the hydrolysis of GlcCer by the enzyme glucosylceramidase (also known as beta-glucosidase), which removes the glucose molecule from the ceramide. The resulting ceramide can then be further metabolized through various pathways, leading to the production of free fatty acids, sphingosine, and other metabolites. Deficiency in glucosylceramidase activity can lead to the accumulation of GlcCer in cells, which can cause various disorders, including Gaucher disease. The breakdown of GlcCer is also important for the regulation of signaling pathways involved in cell growth, differentiation, and apoptosis. This process is tightly regulated by various factors, including the availability of substrates, the activity of enzymes involved, and the expression of genes involved in the pathway.'
"
| Protein | Definition | Taxonomy |
|---|---|---|
| Lysosomal acid glucosylceramidase | A lysosomal acid glucosylceramidase that is encoded in the genome of cow. [OMA:Q2KHZ8, PRO:DNx] | Bos taurus (cattle) |
| Non-lysosomal glucosylceramidase | A non-lysosomal glucosylceramidase that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q9HCG7] | Homo sapiens (human) |
| Cytosolic beta-glucosidase | A cytosolic beta-glucosidase that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q9H227] | Homo sapiens (human) |
| Cytosolic beta-glucosidase | A cytosolic beta-glucosidase that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q9H227] | Homo sapiens (human) |
| Lysosomal acid glucosylceramidase | A lysosomal acid glucosylceramidase that is encoded in the genome of human. [PRO:DNx, UniProtKB:P04062] | Homo sapiens (human) |
| Compound | Definition | Classes | Roles |
|---|---|---|---|
| ambroxol | Ambroxol: A metabolite of BROMHEXINE that stimulates mucociliary action and clears the air passages in the respiratory tract. It is usually administered as the hydrochloride. | aromatic amine | |
| beta-glucono-1,5-lactone | beta-glucono-1,5-lactone: structure D-glucono-1,5-lactone : An aldono-1,5-lactone obtained from D-gluconic acid. | aldono-1,5-lactone; gluconolactone | animal metabolite; mouse metabolite |
| 1-deoxynojirimycin | 1-deoxy-nojirimycin: structure in first source duvoglustat : An optically active form of 2-(hydroxymethyl)piperidine-3,4,5-triol having 2R,3R,4R,5S-configuration. | 2-(hydroxymethyl)piperidine-3,4,5-triol; piperidine alkaloid | anti-HIV agent; anti-obesity agent; bacterial metabolite; EC 3.2.1.20 (alpha-glucosidase) inhibitor; hepatoprotective agent; hypoglycemic agent; plant metabolite |
| miglustat | miglustat : A hydroxypiperidine that is deoxynojirimycin in which the amino hydrogen is replaced by a butyl group. miglustat: a glucosylceramide synthase inhibitor | piperidines; tertiary amino compound | anti-HIV agent; EC 2.4.1.80 (ceramide glucosyltransferase) inhibitor |
| castanospermine | castanospermine : A tetrahydroxyindolizidine alkaloid that consists of octahydroindolizine having four hydroxy substituents located at positions 1, 6, 7 and 8 (the 1S,6S,7R,8R,8aR-diastereomer). castanospermine: indolizidine alkaloid from seeds of Australian legume, Castanospermum australe | indolizidine alkaloid | anti-HIV-1 agent; anti-inflammatory agent; EC 3.2.1.* (glycosidase) inhibitor; metabolite |
| n-phenylphthalimide | N-phenylphthalimide: structure given in first source | ||
| fagomine | fagomine: structure in first source | piperidines | |
| N-Benzylphthalimide | isoindoles | ||
| 1-(10h-phenothiazin-2-yl)ethanone | 1-(10H-phenothiazin-2-yl)ethanone: structure in first source | phenothiazines | |
| mor-14 | N-methyldeoxynojirimycin: glucosidase inhibitor | hydroxypiperidine; piperidine alkaloid; tertiary amino compound | anti-HIV agent; cardioprotective agent; EC 3.2.1.20 (alpha-glucosidase) inhibitor; plant metabolite |
| 1,2,3,4-tetrahydroxy-nor-tropane | calystegine B(2): RN given for (2-endo,3-exo,4-endo)-isomer; structure in first source | ||
| 2,5-dihydroxymethyl-3,4-dihydroxypyrrolidine | 2,5-dihydroxymethyl-3,4-dihydroxypyrrolidine: structure given in first source | dihydroxypyrrolidine | |
| homonojirimycin | homonojirimycin: inhibits alpha-glucosidase; RN given for (2R-(2alpha,3alpha,4beta,5alpha,6beta))-isomer; structure in first source | ||
| cyclophellitol | cyclophellitol: structure given in first source; isolated from Phellinus sp. | ||
| migalastat | migalastat: a potent inhibitor of glycolipid biosynthesis | piperidines | |
| calystegine a3 | calystegine A3: also inhibits beta-xylosidase; structure in first source | ||
| miglitol | piperidines | ||
| 2,5-dideoxy-2,5-imino-d-glucitol | 2,5-dideoxy-2,5-imino-D-glucitol: structure in first source | ||
| validamine | validamine : An amino cyclitol consisting of 1D-chiro-inositol lacking the 6-hydroxy group and having those at positions 1 and 5 replaced by amino and hydroxymethyl groups respectively. validamine: RN given from CA Index Guide; RN not in Chemline 11/84; structure given in first source | amino cyclitol | |
| isofagomine | piperidines | ||
| 1,4-dideoxy-1,4-imino-d-arabinitol | |||
| n-nonyl-1-deoxynojirimycin | N-nonyldeoxynojirimycin : A hydroxypiperidine that is deoxynojirimycin (duvoglustat) in which the amino hydrogen is replaced by a nonyl group. | hydroxypiperidine; tertiary amino compound | antiviral agent; EC 3.2.1.20 (alpha-glucosidase) inhibitor; EC 3.2.1.45 (glucosylceramidase) inhibitor |
| 1-(1-benzimidazolyl)-3-(1-cyclohex-3-enylmethoxy)-2-propanol | benzimidazoles | ||
| 2-(2-phenylethylthio)-3-pyridinecarboxylic acid | aromatic carboxylic acid; pyridines | ||
| 4-(2-furanylmethyl)-3-(phenylmethyl)-1H-1,2,4-triazole-5-thione | benzenes | ||
| 2-[[4-(4-chloroanilino)-6-(1-pyrrolidinyl)-1,3,5-triazin-2-yl]amino]ethanol | dialkylarylamine; tertiary amino compound | ||
| 4-(benzenesulfonamido)-N-(5-ethyl-1,3,4-thiadiazol-2-yl)benzamide | sulfonamide | ||
| tamoxifen | stilbenoid; tertiary amino compound | angiogenesis inhibitor; antineoplastic agent; bone density conservation agent; EC 1.2.3.1 (aldehyde oxidase) inhibitor; EC 2.7.11.13 (protein kinase C) inhibitor; estrogen antagonist; estrogen receptor antagonist; estrogen receptor modulator | |
| 4-oxido-3-(4-phenoxyphenyl)-4a,5,6,7,8,8a-hexahydroquinoxalin-1-ium 1-oxide | aromatic ether | ||
| 2-[[4-(3-methylanilino)-6-(1-pyrrolidinyl)-1,3,5-triazin-2-yl]amino]ethanol | dialkylarylamine; tertiary amino compound | ||
| N-(1-benzylpiperidin-4-yl)-2-(pyridin-3-yl)quinazolin-4-amine | N-(1-benzylpiperidin-4-yl)-2-(pyridin-3-yl)quinazolin-4-amine : A member of the class of quinazolines that is quinazoline which is substituted by a pyridin-3-yl group and a (1-benzylpiperidin-4-yl)nitrilo group at positions 2 and 4, respectively. | aromatic amine; piperidines; pyridines; quinazolines; secondary amino compound; tertiary amino compound | |
| N-[4-methyl-2-(4-morpholinyl)-6-quinolinyl]cyclohexanecarboxamide | aminoquinoline | ||
| n-(5-adamantane-1-yl-methoxy-pentyl)deoxynojirimycin | |||
| ogt2378 | sinbaglustat: an antineopl agent; structure in first source | ||
| nnc 26-9100 | NNC 26-9100: structure in first source | aminopyridine | |
| 3-epi-fagomine | 3-epi-fagomine : A member of the class of hydroxypiperidines that is piperidine carrying a hydroxymethyl substituent at position 2 as well as two hydroxy substituents at positions 3 and 4 (the 2R,3R,4S-diastereomer). | amino monosaccharide; hydroxypiperidine; primary alcohol; secondary alcohol; secondary amino compound; triol | EC 3.2.1.10 (oligo-1,6-glucosidase) inhibitor; EC 3.2.1.23 (beta-galactosidase) inhibitor; plant metabolite |
| l-altro-1-deoxynojirimycin | L-altro-1-deoxynojirimycin: structure in first source | ||
| 2-[[4-[2-[(2-methylpropan-2-yl)oxy]anilino]-6-(1-pyrrolidinyl)-1,3,5-triazin-2-yl]amino]ethanol | aromatic ether | ||
| 2-[[4-(5-chloro-2-methoxyanilino)-6-(1-piperidinyl)-1,3,5-triazin-2-yl]amino]ethanol | methoxybenzenes; substituted aniline | ||
| 2-[[4-(4-methylanilino)-6-(1-pyrrolidinyl)-1,3,5-triazin-2-yl]amino]ethanol | dialkylarylamine; tertiary amino compound | ||
| 2-[[4-(2-chloroanilino)-6-(1-pyrrolidinyl)-1,3,5-triazin-2-yl]amino]ethanol | dialkylarylamine; tertiary amino compound | ||
| 2-[[4-(2-methoxyanilino)-6-(1-pyrrolidinyl)-1,3,5-triazin-2-yl]amino]ethanol | methoxybenzenes; substituted aniline | ||
| 2-[[4-(3-methoxyanilino)-6-(1-pyrrolidinyl)-1,3,5-triazin-2-yl]amino]ethanol | methoxybenzenes; substituted aniline | ||
| 2-[[4-(4-methoxyanilino)-6-(1-pyrrolidinyl)-1,3,5-triazin-2-yl]amino]ethanol | methoxybenzenes; substituted aniline | ||
| 2-[[4-(2-hydroxyethylamino)-6-(1-pyrrolidinyl)-1,3,5-triazin-2-yl]amino]phenol | dialkylarylamine; tertiary amino compound | ||
| 2-[[4-(2-phenoxyanilino)-6-(1-pyrrolidinyl)-1,3,5-triazin-2-yl]amino]ethanol | aromatic ether | ||
| 2-[[4-(1-pyrrolidinyl)-6-[2-(trifluoromethoxy)anilino]-1,3,5-triazin-2-yl]amino]ethanol | aromatic ether | ||
| 2-[[4-(5-chloro-2-ethoxyanilino)-6-(1-pyrrolidinyl)-1,3,5-triazin-2-yl]amino]ethanol | aromatic ether | ||
| 2-[[4-(5-chloro-2-propan-2-yloxyanilino)-6-(1-pyrrolidinyl)-1,3,5-triazin-2-yl]amino]ethanol | aromatic ether |